Valeant Pharmaceuticals International (VRX): Price Target and June Short Interest Disclosure

Valeant Pharmaceuticals International (VRX) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $90 and the lowest price target forecast is $11. The average forecast of all the analysts is $39.75 and the expected standard deviation is $19.53.

Valeant Pharmaceuticals International (VRX), According to the latest information the short interest in Valeant Pharmaceuticals Intl plummeted by 7.2% or 2,357,896 shares. The final shorts are 9.1% of the total floated shares. The positions dropped from 32,604,364 shares on June 15,2016 to 30,246,468 on June 30,2016. According to the per-day average trading of 22,701,840 shares, the days to cover are 1. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.

Also, BMO Capital initiates coverage on Valeant Pharmaceuticals International (NYSE:VRX) The brokerage firm has issued a Market Perform rating on the shares. The rating by the firm was issued on June 29, 2016.


Valeant Pharmaceuticals International (NYSE:VRX): stock turned positive on Thursday. Though the stock opened at $21.91, the bulls momentum made the stock top out at $23.2 level for the day. The stock recorded a low of $21.45 and closed the trading day at $23.02, in the green by 6.48%. The total traded volume for the day was 49,842,743. The stock had closed at $21.62 in the previous days trading.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.